Current understanding of the molecular biology of pancreatic neuroendocrine tumors

Journal of the National Cancer Institute

Volumn 105, Issue 14, 2013, Pages 1005-1017

  Zhang, Jianliang ^a   Francois, Rony ^b   Iyer, Renuka ^a   Seshadri, Mukund ^a   Zajac Kaye, Maria ^b   Hochwald, Steven N ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRX PROTEIN; BEVACIZUMAB; CELL PROTEIN; DAXX PROTEIN; EVEROLIMUS; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; MENIN AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INHIBITOR; PROTEIN RET; RET INHIBITOR; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG;

CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INTERACTION; CELL PROLIFERATION; DISEASE FREE SURVIVAL; DNA SEQUENCE; DRUG EFFICACY; DRUG TARGETING; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GENE INACTIVATION; GENE MUTATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; MOLECULAR BIOLOGY; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PANCREAS ISLET CELL; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; VON HIPPEL LINDAU DISEASE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE KNOCK-IN TECHNIQUES; GENE KNOCKOUT TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDOLES; ISLETS OF LANGERHANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROENDOCRINE TUMORS; NUCLEAR PROTEINS; OCTREOTIDE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PYRROLES; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84880567834     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt135     Document Type: Review

References (110)

1. Couvelard A. Neuroendocrine tumours of the pancreas: recent developments in staging and grading. Diagnostic Histopathol. 2012;18(1):1-7.
2. Franko J, Feng W, Yip L, et al. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J Gastrointest Surg. 2010;14(3):541-548.
3. Bilimoria KY, Tomlinson JS, Merkow R P, et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg. 2007;11(11):1460-1467; discussion 1467-1469.
4. Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008;19(10):1727-1733.
5. Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39(6):707-712.
6. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta. 2012;1826(2):255-271.
7. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340(11): 858-868. (Pubitemid 29142631)
8. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492-3500. (Pubitemid 350160130)
9. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063- 3072.
10. Reichert M, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest. 2011;121(12):4572-4578.
11. Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29(22):3044-3049.
12. Bruzoni M, Johnston E, Sasson AR. Pancreatic incidentalomas: clinical and pathologic spectrum. Am J Surg. 2008;195(3):329-332; discussion 332. (Pubitemid 351625120)
13. Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256(2):321-325.
14. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36(7):933-942.
15. Steve Jobs's cancer. Pancreatic neuroendocrine tumors are becoming more common (the bad news) and also more treatable (the good news). Harv Health Lett. 2012;37(3):1-3.
16. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol. 2012;24(1):46-55.
17. Ishida E, Yamada M, Horiguchi K, et al. Attenuated expression of menin and p27 (Kip1) in an aggressive case of multiple endocrine neoplasia type 1 (MEN1) associated with an atypical prolactinoma and a malignant pancreatic endocrine tumor. Endocr J. 2011;58(4):287-296.
18. Loffler KA, Mould AW, Waring PM, et al. Menin and p53 have non-synergistic effects on tumorigenesis in mice. BMC Cancer. 2012;12(1):252.
19. Virtanen I, Banerjee M, Palgi J, et al. Blood vessels of human islets of Langerhans are surrounded by a double basement membrane. Diabetologia. 2008;51(7):1181-1191.
20. Nikolova G, Jabs N, Konstantinova I, et al. The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell. 2006;10(3):397-405.
21. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331(6021):1199-1203.
22. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276(5311):404- 407.
23. Krausch M, Raffel A, Anlauf M, et al. Loss of PTEN expression in neuroendocrine pancreatic tumors. Horm Metab Res. 2011;43(12):865-871.
24. Krymskaya V P, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle. 2009;8(3):403-413.
25. Larson AM, Hedgire SS, Deshpande V, et al. Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet. 2012;82(6):558-563.
26. Arva NC, Pappas JG, Bhatla T, et al. Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis - case report and review of the literature. Am J Surg Pathol. 2012;36(1):149-153.
27. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol. 2010;28(2):245-255.
28. Zitzmann K, Vlotides G, Brand S, et al. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms. Endocr Relat Cancer. 2012;19(3):423-434.
29. Gloesenkamp CR, Nitzsche B, Ocker M, et al. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors. Int J Oncol. 2012;40(3):876-888.
30. Ghayouri M, Boulware D, Nasir A, et al. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. AntiCancer Res. 2010;30(12):5063-5067.
31. Shah T, Hochhauser D, Frow R, et al. Epidermal growth factor receptor expression and activation in neuroendocrine tumours. J Neuroendocrinol. 2006;18(5):355-360.
32. Yap TA, Yan L, Patnaik A, et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol. 2011;29(35):4688-4695.
33. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18(16):1926-1945. (Pubitemid 39071573)
34. Tokunaga C, Yoshino K, Yonezawa K. mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun. 2004;313(2):443-446. (Pubitemid 37543606)
35. Zhou CF, Ji J, Yuan F, et al. mTOR activation in well differentiated pancreatic neuroendocrine tumors: a retrospective study on 34 cases. Hepato-Gastroenterology. 2011;58(112):2140-2143.
36. Chiu CW, Nozawa H, Hanahan D. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis. J Clin Oncol. 2010;28(29):4425-4433.
37. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010;24(3):355-370.
38. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954;16(3):363-371.
39. Corbo V, Dalai I, Scardoni M, et al. MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocr Relat Cancer. 2010;17(3):771-783.
40. Bertolino P, Radovanovic I, Casse H, et al. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev. 2003;120(5):549-560. (Pubitemid 36623317)
41. Crabtree JS, Scacheri PC, Ward JM, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A. 2001;98(3):1118-1123. (Pubitemid 32121196)
42. Crabtree JS, Scacheri PC, Ward JM, et al. Of mice and MEN1: Insulinomas in a conditional mouse knockout. Mol Cell Biol. 2003;23(17):6075-6085. (Pubitemid 37013087)
43. Bertolino P, Tong WM, Herrera PL, et al. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res. 2003;63(16):4836-4841. (Pubitemid 37022614)
44. Zhang H, Li W, Wang Q, et al. Glucose-mediated repression of menin promotes pancreatic beta-cell proliferation. Endocrinology. 2012;153(2):602-611.
45. Gao SB, Feng ZJ, Xu B, et al. Menin represses malignant phenotypes of melanoma through regulating multiple pathways. J Cell Mol Med. 2011;15(11):2353-2363.
46. Karnik SK, Chen H, McLean GW, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science. 2007;318(5851):806-809. (Pubitemid 351411773)
47. van Wijk J P, Dreijerink KM, Pieterman CR, et al. Increased prevalence of impaired fasting glucose in MEN1 gene mutation carriers. Clin Endocrinol (Oxf). 2012;76(1):67-71.
48. Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci U S A. 2005;102(41):14659-14664. (Pubitemid 41457112)
49. Schnepp RW, Chen YX, Wang H, et al. Mutation of tumor suppressor gene Men1 acutely enhances proliferation of pancreatic islet cells. Cancer Res. 2006;66(11):5707-5715. (Pubitemid 43927123)
50. Murai MJ, Chruszcz M, Reddy G, et al. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem. 2011;286(36):31742-31748.
51. Yokoyama A, Somervaille TC, Smith KS, et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell. 2005;123(2):207-218. (Pubitemid 41457212)
52. Wu T, Hua X. Menin represses tumorigenesis via repressing cell proliferation. Am J Cancer Res. 2011;1(6):726-739.
53. Taguchi R, Yamada M, Horiguchi K, et al. Haploinsufficient and predominant expression of multiple endocrine neoplasia type 1 (MEN1)-related genes, MLL, p27Kip1 and p18Ink4C in endocrine organs. Biochem Biophys Res Commun. 2011;415(2):378-383.
54. Li Q, Wang X, Wu X, et al. Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death. Cancer Res. 2007;67(1):66-74. (Pubitemid 46142760)
55. Kilkenny DM, Rocheleau JV. Fibroblast growth factor receptor-1 signaling in pancreatic islet beta-cells is modulated by the extracellular matrix. Mol Endocrinol. 2008;22(1):196-205.
56. Tang J, Wu S, Liu H, et al. A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. J Biol Chem. 2004;279(19):20369-20377. (Pubitemid 38623483)
57. Lewis PW, Elsaesser SJ, Noh KM, et al. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. Proc Natl Acad Sci U S A. 2010;107(32):14075-14080.
58. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011;333(6041):425.
59. de Wilde RF, Edil BH, Hruban RH, et al. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol. 2012;9(4):199-208.
60. Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery. 2000;128(6):1022-1027;discussion 1027-1028.
61. Schmitt AM, Schmid S, Rudolph T, et al. VHL inactivation is an important pathway for the development of malignant sporadic pancreatic endocrine tumors. Endocr Relat Cancer. 2009;16(4):1219-1227.
62. Speisky D, Duces A, Bieche I, et al. Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patients. Clin Cancer Res. 2012;18(10):2838-49.
63. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett. 2004;204(2):197-211. (Pubitemid 38167723)
64. Nagano Y, Kim do H, Zhang L, et al. Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis. Endocr Relat Cancer. 2007;14(2):483-492. (Pubitemid 47242646)
65. Sippel RS, Carpenter JE, Kunnimalaiyaan M, et al. Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2003;285(2):G245-254. (Pubitemid 36875195)
66. Lim Y, Park H, Jeon J, et al. Focal adhesion kinase is negatively regulated by phosphorylation at tyrosine 407. J Biol Chem. 2007;282(14):10398- 10404. (Pubitemid 47093453)
67. Ning L, Chen H, Kunnimalaiyaan M. Focal adhesion kinase, a downstream mediator of Raf-1 signaling, suppresses cellular adhesion, migration, and neuroendocrine markers in BON carcinoid cells. Mol Cancer Res. 2010;8(5):775-782.
68. Evers BM, Townsend CM, Jr., Upp JR, et al. Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth. Gastroenterology. 1991;101(2):303-311.
69. Campbell PM, Groehler AL, Lee KM, et al. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 2007;67(5):2098-2106. (Pubitemid 46424228)
70. Gibbons RJ, Picketts DJ, Villard L, et al. Mutations in a putative global transcriptional regulator cause X-linked mental retardation with alpha-thalassemia (ATR-X syndrome). Cell. 1995;80(6):837-845.
71. Picketts DJ, Higgs DR, Bachoo S, et al. ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet. 1996;5(12):1899-1907. (Pubitemid 26413632)
72. Straub AC, Lohman AW, Billaud M, et al. Endothelial cell expression of haemoglobin alpha regulates nitric oxide signalling. Nature. 2012;491(7424):473-477.
73. Tejedo JR, Cahuana GM, Ramirez R, et al. nitric oxide triggers the phosphatidylinositol 3-kinase/Akt survival pathway in insulin-producing RINm5F cells by arousing Src to activate insulin receptor substrate-1. Endocrinology. 2004;145(5):2319-2327. (Pubitemid 38535061)
74. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab. 2005;90(7):4350-4356. (Pubitemid 41058218)
75. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2005;289(4):G636-642. (Pubitemid 41377169)
76. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, et al. Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist. 2007;12(8):942-951. (Pubitemid 47359136)
77. Mohammed TA, Holen KD, Jaskula-Sztul R, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011;16(6):835-843.
78. Yachida S, Vakiani E, White CM, et al. Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol. 2012;36(2):173-184.
79. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology. 1998;32(2):133-138. (Pubitemid 28126179)
80. Couvelard A, O'Toole D, Turley H, et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer. 2005;92(1):94-101. (Pubitemid 40188441)
81. Poncet G, Villaume K, Walter T, et al. Angiogenesis and tumor progression in neuroendocrine digestive tumors. J Surg Res. 2009;154(1):68-77.
82. Konstantinova I, Lammert E. Microvascular development: learning from pancreatic islets. Bioessays. 2004;26(10):1069-1075. (Pubitemid 39424810)
83. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol. 1995;9(12):1760-1770.
84. Inoue M, Hager JH, Ferrara N, et al. VEGF - A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell. 2002;1(2):193-202. (Pubitemid 41039165)
85. Lammert E, Gu G, McLaughlin M, et al. Role of VEGF - A in vascularization of pancreatic islets. Curr Biol. 2003;13(12):1070-1074. (Pubitemid 36726045)
86. Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. Science. 2001;294(5542):564-567. (Pubitemid 32999547)
87. Henderson JR, Moss MC. A morphometric study of the endocrine and exocrine capillaries of the pancreas. Q J Exp Physiol. 1985;70(3):347-356. (Pubitemid 15070871)
88. Jansson L, Carlsson PO. Graft vascular function after transplantation of pancreatic islets. Diabetologia. 2002;45(6):749-763.
89. Fjallskog ML, Lejonklou MH, Oberg KE, et al. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res. 2003;9(4):1469-1473. (Pubitemid 36418403)
90. Fjallskog ML, Hessman O, Eriksson B, et al. Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. Acta Oncol. 2007;46(6):741-746. (Pubitemid 47123755)
91. Marion-Audibert AM, Barel C, Gouysse G, et al. Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology. 2003;125(4):1094-1104. (Pubitemid 37193456)
92. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677-684. (Pubitemid 36749216)
93. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843-845.
94. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468. (Pubitemid 32335941)
95. Aragones J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008;40(2):170-180. (Pubitemid 351171394)
96. Couvelard A, Deschamps L, Rebours V, et al. Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res. 2008;14(20):6634-6639.
97. Detjen KM, Rieke S, Deters A, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res. 2010;16(2):420-429.
98. Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Ther Clin Risk Manag. 2007;3(2):341-348. (Pubitemid 46881462)
99. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-513.
100. Blumenthal GM, Cortazar P, Zhang JJ, et al. FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. Oncologist. 2012;17(8):1108- 1113.
101. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96(12):3741-3749.
102. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):514-523.
103. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378(9808):2005-2012.
104. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592-603.
105. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer. 2010;46(8):1323-1332.
106. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210-221.
107. Sennino B, Ishiguro-Oonuma T, Wei Y, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;2(3):270-287.
108. Mologni L. Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem. 2011;18(2):162-175.
109. Mologni L, Sala E, Cazzaniga S, et al. Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol. 2006;37(2):199-212. (Pubitemid 44615293)
110. Hobday TJ JR, Reidy L, et al. Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET). J Clin Oncol. 2012;30(suppl 4):abstract 260.